Immune cell treatment for recovery from severe septic shock
Part of Infections clinical trials.
This trial tests an immune-cell treatment given outside the body to help people recover from septic shock, a life-threatening reaction to infection. It aims to improve survival and organ recovery in patients who are still very ill despite standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (18 or older).
- You must have septic shock diagnosed recently (within 48 hours before starting the study).
- Your blood lactate level must be high (>2 mmol/L) even after fluids have been given.
- Your blood pressure support medicines (like norepinephrine and/or vasopressin) must be needed for at least 6 hours to keep blood pressure up.
- You need central IV access and an arterial line, and these must stay in place for the first 48 hours.
- A doctor must agree the infection source is treated or actively being treated, and you (or your legal representative) must be able to consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how special cells from bone marrow (called stem cells) might help fix immune problems caused by sepsis. The goal is to see if these cells can improve how your immune system works during a severe infection.
This trial is testing several different treatments to find the best one for each person with sepsis. It looks at specific 'treatable traits' like inflammation, blood clotting problems, or immune system issues to match you with the right therapy. The goal is to improve recovery and survival.
This study is collecting real-world data on ARTICE® treatment for adults in the ICU. It helps doctors understand how this treatment works in daily practice.
This study checks on people who had septic shock and were in the ReActIF-ICE trial. It looks at how their immune system recovered over time after an experimental therapy.
This Phase 2 trial tests an immune-boosting cell therapy (umbilical mesenchymal stromal cells) in people with septic shock—when infection causes dangerous stress on the heart and other organs. The goal is to see if this treatment can improve outcomes compared with standard care.
This trial tests a new treatment to protect and repair the layer of cells lining your blood vessels (glycocalyx) during sepsis. It aims to improve recovery from severe infections.
Hear when a new Sepsis, Severe trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.